HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company,” Pink Sheets: TAROF) today reported that it received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (“ANDA”) for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg and 400 mg (“carbamazepine extended-release tablets”).
